Kevin Winthrop, MD, MPH

Kevin Winthrop, MD, MPHKevin Winthrop, MD, MPH
Associate Professor of Infectious Diseases, Ophthalmology,
Professor of Public Health and Preventive Medicine (joint appointment),
Division of Infectious Diseases, OHSU


Internal Medicine, Mycobacterial Diseases, Public Health and Infectious Disease Epidemiology


B.A. - Yale University
M.D. - Oregon Health & Science University
M.P.H. (Epidemiology) - University of California at Berkeley

Professional Training:

Residency (Ophthalmology) - Stanford University
Epidemic Intelligence Service Officer - US Public Health Service, US Centers for Diseases Control and Prevention
Residency (Internal Medicine) - Legacy Emanuel Hospital, Portland, Oregon
Fellowship (Mycobacterial Diseases) - National Jewish Medical Center, Denver, Colorado

Clinical Interests

  • Chronic chest infections of all etiology, including mycobacteria
  • The prevention and treatment of infections associated with Biologics and other Immunosuppressive therapies
  • Tuberculosis of the eye (Ophthalmology)

Research Interests:

  • Onchocerchiasis (river blindness) treatment and diagnosis
  • Prevention and treatment of opportunistic infections in patients receiving novel immunosuppressive therapies
  • Epidemiology of tuberculosis and non-TB mycobacterial infections
  • International ophthalmology education and training
  • Therapeutic development and clinical trials related to bronchiectasis, NTM, and other chronic chest infections

  • Epidemiology and prevention of herpes zoster

Brief Bio:

Kevin Winthrop, M.D., M.P.H. – is principal investigator and Director of the Center for Infectious Disease Studies. Dr. Winthrop is a Professor of Public Health at the School of Public Health and an Associate Professor of Infectious Diseases and Ophthalmology at the School of Medicine at OHSU. He is a former infectious disease epidemiologist with the Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention.

Representative Publications:

  1. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H… Bananis E. (2017). Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol. doi: 10.1002/art.40189. [Epub ahead of print]

  2. Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI… Rigby WF. (2017). The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol. doi: 10.1002/art.40187. [Epub ahead of print]

  3. Winthrop, K. L., Strand, V., van der Heijde, D., Mease, P., Crow, M., Weinblatt, M., . . . Furst, D. E. (2017). The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. doi:10.1016/j.clim.2017.08.009
  4. Winthrop, K. L., Lebwohl, M., Cohen, A. D., Weinberg, J. M., Tyring, S. K., Rottinghaus, S. T., . . . Valdez, H. (2017). Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol, 77(2), 302-309. doi:10.1016/j.jaad.2017.03.023
  5. Rose-John, S., Winthrop, K., & Calabrese, L. (2017). The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol, 13(7), 399-409. doi:10.1038/nrrheum.2017.83
  6. Papp, K. A., Bachelez, H., Blauvelt, A., Winthrop, K. L., Romiti, R., Ohtsuki, M., . . . Strober, B. (2017). Infections from 7 Clinical Trials of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis. Br J Dermatol. doi:10.1111/bjd.15723
  7. Kay, J., & Winthrop, K. L. (2017). Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". Nat Rev Rheumatol, 13(7), 391-392. doi:10.1038/nrrheum.2017.79
  8. Ruffner, M. A., Aksamit, T. R., Thomashow, B., Choate, R., DiMango, A., Turino, G. M., . . . Sullivan, K. E. (2017). Frequency of untreated hypogammaglobulinemia in bronchiectasis. Ann Allergy Asthma Immunol, 119(1), 83-85. doi:10.1016/j.anai.2017.04.020
  9. Aksamit, T., Bandel, T. J., Criollo, M., De Soyza, A., Elborn, J. S., Operschall, E., . . . Wilson, R. (2017). The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemp Clin Trials, 58, 78-85. doi:10.1016/j.cct.2017.05.007
  10. Henkle, E., Aksamit, T. R., Barker, A. F., Curtis, J. R., Daley, C. L., Anne Daniels, M. L., . . . Winthrop, K. L. (2017). Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. doi:10.1016/j.chest.2017.04.167
  11. Park, J. K., Lee, M. A., Lee, E. Y., Song, Y. W., Choi, Y., Winthrop, K. L., & Lee, E. B. (2017). Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis, 76(9), 1559-1565. doi:10.1136/annrheumdis-2017-211128
  12. Henkle, E., Novosad, S. A., Shafer, S., Hedberg, K., Siegel, S. A. R., Ku, J., . . . Winthrop, K. L. (2017). Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. Ann Am Thorac Soc, 14(7), 1120-1128. doi:10.1513/AnnalsATS.201610-801OC
  13. Novosad, S. A., Henkle, E., Schafer, S., Hedberg, K., Ku, J., Siegel, S. A. R., . . . Winthrop, K. L. (2017). Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria. Ann Am Thorac Soc, 14(7), 1112-1119. doi:10.1513/AnnalsATS.201610-800OC
  14. Winthrop, K. L. (2017). The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol, 13(4), 234-243. doi:10.1038/nrrheum.2017.23
  15. Yun, H., Xie, F., Baddley, J. W., Winthrop, K., Saag, K. G., & Curtis, J. R. (2017). Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol, 44(7), 1083-1087. doi:10.3899/jrheum.160685

Back to ID Faculty Listing